<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36287176</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3-4</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>288</EndPage><MedlinePgn>281-288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2136994</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Provide US FDA and amyotrophic lateral sclerosis (ALS) society with a systematic, transparent, and quantitative framework to evaluate the efficacy of the ALS therapeutic candidate AMX0035 in its phase 2 trial, which showed statistically significant effects (<i>p</i>-value 3%) in slowing the rate of ALS progression on a relatively small sample size of 137 patients.</AbstractText><AbstractText Label="METHODS">We apply Bayesian decision analysis (BDA) to determine the optimal type I error rate (<i>p</i>-value) under which the clinical evidence of AMX0035 supports FDA approval. Using rigorous estimates of ALS disease burden, our BDA framework strikes the optimal balance between FDA's need to limit adverse effects (type I error) and patients' need for expedited access to a potentially effective therapy (type II error). We apply BDA to evaluate long-term patient survival based on clinical evidence from AMX0035 and Riluzole.</AbstractText><AbstractText Label="RESULTS">The BDA-optimal type I error for approving AMX0035 is higher than the 3% <i>p</i>-value reported in the phase 2 trial if the probability of the therapy being effective is at least 30%. Assuming a 50% probability of efficacy and a signal-to-noise ratio of treatment effect between 25% and 50% (benchmark: 33%), the optimal type I error rate ranges from 2.6% to 26.3% (benchmark: 15.4%). The BDA-optimal type I error rate is robust to perturbations in most assumptions except for a probability of efficacy below 5%.</AbstractText><AbstractText Label="CONCLUSION">BDA provides a useful framework to incorporate subjective perspectives of ALS patients and objective burden-of-disease metrics to evaluate the therapeutic effects of AMX0035 in its phase 2 trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qingyang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>MIT Laboratory for Financial Engineering, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Operations Research Center, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Joonhyuk</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MIT Laboratory for Financial Engineering, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Chaouch</LastName><ForeName>Zied</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>MIT Laboratory for Financial Engineering, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Andrew W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>MIT Laboratory for Financial Engineering, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Operations Research Center, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Sloan School of Management, Cambridge, MA, USA, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sante Fe Institute, Santa Fe, NM, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000723627">sodium phenylbutyrate and taurursodiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="N">Patient Preference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Bayesian decision analysis</Keyword><Keyword MajorTopicYN="N">clinical trial development</Keyword><Keyword MajorTopicYN="N">patient value</Keyword><Keyword MajorTopicYN="N">pharmaceutical regulation</Keyword><Keyword MajorTopicYN="N">survival analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36287176</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2136994</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>